Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma
Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
People on Ozempic may have fewer heart attacks, strokes, addictions—but more nausea, vomiting, stomach pain
Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity.
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Futurism on MSN17h
Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...
TAG24 NEWS on MSN10m
Major study of weight-loss jabs shows slew of benefits but also risks
Hugely popular weight-loss jabs like Wegovy have been making headlines for enabling people to manage diabetes and excess weight along with other benefits, scientists say.Increasingly recommended by ...